BCLI: Brainstorm Cell Therapeutics Inc. Stocks News on June 28, 2025

BCLI

MT Newswires

3 days ago

Brainstorm Cell Therapeutics Files for Resale of 2.76 Million Shares by Investor

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

BCLI

PR Newswire

12 days ago

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

7 Summer Side Hustles That Can Pay $1,000 a Week or More

BCLI

GOBankingRates

a month ago

7 Summer Side Hustles That Can Pay $1,000 a Week or More

Will Tesla have to play catch up to Waymo's robotaxis?

BCLI

Yahoo Finance Video

a month ago

Will Tesla have to play catch up to Waymo's robotaxis?

Why Scott Bessent wants to make it easier for banks to own Treasurys

BCLI

Yahoo Finance

a month ago

Why Scott Bessent wants to make it easier for banks to own Treasurys

When are people too old to do their jobs?

BCLI

The Guardian

a month ago

When are people too old to do their jobs?

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

BCLI

GlobeNewswire

a month ago

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

BCLI

GlobeNewswire

a month ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

BCLI

PR Newswire

a month ago

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

Statement by Minister Guilbeault on Portuguese Heritage Month

BCLI

CNW Group

a month ago

Statement by Minister Guilbeault on Portuguese Heritage Month

BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial

BCLI

Clinical Trials Arena

a month ago

BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial

BCLI

Zacks Small Cap Research

a month ago

BCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial…

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

BCLI

PR Newswire

a month ago

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

FDA grants clearance to BrainStorm’s Phase IIIb trial of ALS treatment

BCLI

Clinical Trials Arena

a month ago

FDA grants clearance to BrainStorm’s Phase IIIb trial of ALS treatment

BCLI

GuruFocus.com

a month ago

Brainstorm Cell Therapeutics Inc (BCLI) Q1 2025 Earnings Call Highlights: Pivotal Phase 3b ...

BCLI

Thomson Reuters StreetEvents

a month ago

Q1 2025 Brainstorm Cell Therapeutics Inc Earnings Call

BCLI

MT Newswires

a month ago

Sector Update: Health Care Stocks Advance Monday Afternoon

BCLI

MT Newswires

a month ago

Top Midday Gainers

BCLI

MT Newswires

a month ago

BrainStorm Cleared by FDA to Begin Phase 3b Trial of NurOwn for ALS

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

BCLI

PR Newswire

a month ago

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

BCLI

PR Newswire

a month ago

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19

BCLI

PR Newswire

a month ago

BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025

BCLI

PR Newswire

2 months ago

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025

BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit

BCLI

PR Newswire

2 months ago

BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit

BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting

BCLI

PR Newswire

2 months ago

BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

BCLI

PR Newswire

3 months ago

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS

BCLI

GuruFocus.com

3 months ago

Brainstorm Cell Therapeutics Inc (BCLI) Q4 2024 Earnings Call Highlights: Navigating Financial ...

BCLI

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

BCLI

PR Newswire

3 months ago

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq

BCLI

PR Newswire

3 months ago

BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq

BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update

BCLI

PR Newswire

3 months ago

BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update

BCLI

Zacks Small Cap Research

6 months ago

BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS…

BrainStorm Issues 2024 Letter to Shareholders

BCLI

PR Newswire

6 months ago

BrainStorm Issues 2024 Letter to Shareholders

BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update

BCLI

PR Newswire

7 months ago

BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

BCLI

PR Newswire

7 months ago

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024

BCLI

PR Newswire

7 months ago

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

BCLI

PR Newswire

7 months ago

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

BCLI

PR Newswire

8 months ago

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

BCLI

PR Newswire

8 months ago

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

BCLI

PR Newswire

8 months ago

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

BCLI

PR Newswire

9 months ago

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

BCLI

PR Newswire

9 months ago

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

BCLI

GlobeNewswire

9 months ago

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

BCLI

Zacks Small Cap Research

10 months ago

BCLI: SPA in Place for Phase 3b Trial of NurOwn® in ALS…

BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

BCLI

PR Newswire

10 months ago

BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update

BCLI

CNW Group

a year ago

BCLI Update - Progress Supports Our 10x Plus Value Range Potential

BCLI

Zacks Small Cap Research

a year ago

BCLI: Preparing to Initiate Phase 3b Trial of NurOwn™ Before End of 2024…

BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

BCLI

MT Newswires

a year ago

Brainstorm Cell Therapeutics Prices Registered Direct Offering, Concurrent Private Placement

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

BCLI

PR Newswire

a year ago

BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation

Italian energy company targets Britain for fleet of 20 mini-nukes

BCLI

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

BCLI

Motley Fool

a year ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Seoul resumes loudspeaker propaganda against North

BCLI

AFP

a year ago

Seoul resumes loudspeaker propaganda against North

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

BCLI

Simply Wall St.

a year ago

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

American Software Full Year 2024 Earnings: EPS Beats Expectations

BCLI

Simply Wall St.

a year ago

American Software Full Year 2024 Earnings: EPS Beats Expectations

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

BCLI

Simply Wall St.

a year ago

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

BCLI

Simply Wall St.

a year ago

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

3 Mistakes That Can Get Your Costco Membership Canceled

BCLI

Motley Fool

a year ago

3 Mistakes That Can Get Your Costco Membership Canceled

BCLI

Motley Fool

a year ago

Better AI Stock: Palantir vs. Snowflake

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

BCLI

Motley Fool

a year ago

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

BCLI

Motley Fool

a year ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'

BCLI

AFP

a year ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?

BCLI

Motley Fool

a year ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

BCLI

GuruFocus.com

a year ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

BCLI

GuruFocus.com

a year ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

BCLI

Simply Wall St.

a year ago

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn

BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

BCLI

Zacks Small Cap Research

a year ago

BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

BCLI

Zacks Small Cap Research

a year ago

BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum

BCLI

PR Newswire

a year ago

BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum

Nutriband CEO Publishes Letter to Shareholders

BCLI

ACCESSWIRE

a year ago

Nutriband CEO Publishes Letter to Shareholders

Getaround Secures $20 Million in Financing, Following Strong Q3 2023 Results

BCLI

Business Wire

a year ago

Getaround Secures $20 Million in Financing, Following Strong Q3 2023 Results

Mullen Announces Bollinger Motors Receives Vehicle Orders for 40 B4, Class 4 EV Trucks; Valued at Approximately $6 Million

BCLI

GlobeNewswire

a year ago

Mullen Announces Bollinger Motors Receives Vehicle Orders for 40 B4, Class 4 EV Trucks; Valued at Approximately $6 Million

Sidoti Events, LLC's Virtual January Micro-Cap Conference

BCLI

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

U.S. Global Investors Announces Share Buyback Numbers for December 2023; Provides an Update on Competitive Year-End Performance for Quant Gold ETF

BCLI

GlobeNewswire

a year ago

U.S. Global Investors Announces Share Buyback Numbers for December 2023; Provides an Update on Competitive Year-End Performance for Quant Gold ETF

ECD Auto Design Expects Organic Revenue Growth of Over 50% in 2024 with Continued GAAP Profitability

BCLI

GlobeNewswire

a year ago

ECD Auto Design Expects Organic Revenue Growth of Over 50% in 2024 with Continued GAAP Profitability

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

BCLI

Benzinga

a year ago

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Harte Hanks Extends Line of Credit with Texas Capital Bank

BCLI

ACCESSWIRE

a year ago

Harte Hanks Extends Line of Credit with Texas Capital Bank

Safe Harbor Financial Originates $9 Million First Lien Secured Loan for Major, MSO-Operated Cultivation Facility in Denver, Colorado

BCLI

GlobeNewswire

a year ago

Safe Harbor Financial Originates $9 Million First Lien Secured Loan for Major, MSO-Operated Cultivation Facility in Denver, Colorado

$Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia$

BCLI

GlobeNewswire

a year ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Bright Scholar Filed Annual Report on Form 20-F for Fiscal 2023

BCLI

PR Newswire

a year ago

Bright Scholar Filed Annual Report on Form 20-F for Fiscal 2023

Expion360 Announces Financing Commitments of up to $22.5 Million

BCLI

ACCESSWIRE

a year ago

Expion360 Announces Financing Commitments of up to $22.5 Million

Yoshitsu Co., Ltd Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

BCLI

GlobeNewswire

2 years ago

Yoshitsu Co., Ltd Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

OLD POINT FINANCIAL CORPORATION ANNOUNCES RETIREMENT OF DR. ARTHUR D. GREENE FROM BOARD OF DIRECTORS

BCLI

PR Newswire

2 years ago

OLD POINT FINANCIAL CORPORATION ANNOUNCES RETIREMENT OF DR. ARTHUR D. GREENE FROM BOARD OF DIRECTORS

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

BCLI

PR Newswire

2 years ago

BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments

Are Options Traders Betting on a Big Move in Airgain (AIRG) Stock?

BCLI

Zacks

2 years ago

Are Options Traders Betting on a Big Move in Airgain (AIRG) Stock?

BrainStorm Issues 2023 Letter to Shareholders

BCLI

PR Newswire

2 years ago

Latest Brainstorm Cell Therapeutics Inc. (BCLI) News on June 28, 2025

Share on Social Networks: